The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6650-6657

  Schneeberger, Achim ^a   Koszik, Frieder ^a   Schmid, Walter ^b   Kutil, Raphaela ^a   Stingl, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; EFFECTOR CELL; GENETIC TRANSFECTION; GRANULOCYTE; HOST RESISTANCE; INFLAMMATION; MACROPHAGE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIATION CHIMERA; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033152033     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Zatloukal, K., A. Schneeberger, M. Berger, W. Schmidt, F. Kostik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, et al. 1995. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine: assessment of critical cellular and molecular parameters. J. Immunol. 154:3406.
2. Schmidt, W., T. Schweighoffer, E. Herbst, G. Maass, M. Berger, F. Schilcher, G. Schaeffner, and M. L. Birnstiel. 1995. Cancer vaccines: the interleukin-2 dosage effect. Proc. Natl. Acad. Sci. USA 92:4711.
3. Bannerji, R., C. D. Arroyo, C. Cordon-Cardo, and E. Gilboa. 1994. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152:2324.
4. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149:3627.
5. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. L. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelslein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
6. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217.
7. Pardoll, D. 1992. New strategies for active immunotherapy with genetically engineered tumor cells. Curr. Opin. Immunol. 4:619.
8. Schneeberger, A., F. Koszik, and G. Stingl. 1995. Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J. Invest. Dermatol. 105:110.
9. Zatloukal, K., W. Schmidt, M. Gotten, E. Wagner, G. Stingl, and M. L. Birnstiel. 1993. Somatic gene therapy for cancer: the utility of transferrinfection in generating tumor vaccines. Gene 135:199.
10. Cavallo, F., F. Di Pierro, M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, M. Forni, A. Modesti, and G. Forni. 1993. Protective and curative potential of vaccination with interleukin-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53:5067.
11. Maass, G., W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M. L. Birnstiel, and T. Schweighoffer. 1995. Priming of tumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92:5540.
12. Cloudman, A. M. 1941. The effect of an extrachromosomal influence upon transplanted spontaneous tumors in mice. Science 93:380.
13. Yasumura, Y., A. H. Tashjian, and G. H. Sato. 1966. Establishment of four functional, clonal strains of animal cells in culture. Science 154:1186.
14. Gillis, S., M. M. Ferm, W. Ou, and K. Smith. 1978. T cell growth factor: parameter of production and a quantitative microassay for activity. J. Immunol. 120:2027.
15. Bottomly, K., L. S. Davis, and P. E. Lipsky. 1991. Measurement of human and murine IL-2 and IL-4. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeck, D. H. Margulies, E. M. Shevach, and W. Strober, eds. Wiley & Sons, New York, p. 6.3.
16. Winn, H. J. 1961. Immune mechanisms in homotransplanlation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J. Immunol. 86:228.
17. Blomberg, K., C. Granberg, I. Hemmilä, and T. Lövgren. 1986. Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-reactive method based on time-resolved fluorescence. J. Immunol. Methods 86:225.
18. Stein, K. E., G. A. Schwarting, and D. M. Marcus. 1978. Glycolipid markers of murine lymphocyte subpopulations. J. Immunol. 120:676.
19. M1: reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127: 34.
20. Kasai, M., T. Yoneda, S. Habu, Y. Maruyama, K. Okumura, and T. Tokunaga. 1981. In vivo effect of anti-asialo GM1 antibody on natural killer cell activity. Nature 291:334.
21. Bubenik, J., N. N. Voitenok, J. Kieler, V. S. Prassolow, P. M. Chumakow, D. Bubenikova, J. Simova, and T. Jandlova. 1988. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19:279.
22. Karp, S. E. A., A. Farber, J. C. Salo, P. Hwu, G. Jaffe, A. L. Asher, E. Shiloni, N. P. Restifo, J. J. Mulé, and S. A. Rosenberg. 1993. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. 150:896.
23. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853.
24. Cavallo, F., A. Martin-Fontecha, M. Hellene, S. Heltai, E. Gatti, P. Tornaghi, M. Freschi, G. Form, P. Dellabona, and G. Casorati. 1995. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25:1154.
25. Wu, T.-C, A. Y. C. Huang, E. M. Jaffee, H. I. Levitsky, and D. M. Pardoll. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415.
26. Geldhof, A. B., G. Raes, M. Bakkus, S. Devos, K. Thielemans, and P. De Baetselier. 1995. Expression of B7-1 by highly metastatic mouse lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 55: 2730.
27. Yeh, K.-Y., B. A. Pulaski, M. L. Woods, A. J. McAdam, A. A. Gaspari, J. G. Frelinger, and E. M. Lord. 1995. B7-1 enhances natural killer cell-mediated cytotoxicily and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165:217.
28. Nandi, D., J. A. Gross, and J. P. Allison. 1994. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J. Immunol. 152:3361.
29. Chambers, B. J., M. Salcedo, and H.-G. Ljunggren. 1996. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311.
30. Cotran, R. S., J. S. Pober, M. A. Gimbrone, T. A. Springer, E. A. Wiebke, A. A. Gaspari, S. A. Rosenberg, and M. T. Lotze. 1987. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J. Immunol. 139:1883.
31. Rand, T. H., D. S. Silberstein, H. Kornfeld, and P. F. Weller. 1991. Human eosinophils express functional interleukin 2 receptors. J. Clin. Invest. 88:825.
32. Kornfeld, H., J. S. Bergman, D. J. Beer, and D. M. Center. 1985. Induction of human T lymphocyte motility by interleukin 2. J. Immunol. 134:3887.
33. Natuk, R. J., and R. M. Welsh. 1987. Chemotactic effect of human recombinant interleukin 2 on mouse activated large granular lymphocytes. J. Immunol. 139: 2737.
34. Hedrik, J. A., and A. Zlotnik. 1996. Chemokines and lymphocyte biology. Curr. Opin. Immunol. 8:343.
35. Kaplan, G., R. Kiessling, S. Teklemariam, G. Hancock, G. Sheftel, K. B. Job, P. Converse, T. H. M. Ottenhoff, M. Becx-Bleumink, M. Dietz, and Z. A. Cohn. 1989. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J. Exp. Med. 169:893.
36. Nagler, A., L. L. Lanier, and J. H. Phillips. 1990. Constitutive expression of high affinity interleukin 2 receptors on human CD 16 natural killer cells in vivo. J. Exp. Med. 171:1527.
37. Gidlund, M., A. Örn, H. Wigrell, A. Senik, and I. Gresser. 1978. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273: 759.
38. Yokoyama, W. M. 1995. Right-side-up and up-side-down NK cell receptors. Curr. Biol. 5:982.
39. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
40. Biron, C. A. 1997. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9:24.
41. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 329:86.
42. Fakhrai, H., D. L. Shawler, R. Gjerset, R. K. Naviaux, J. Koziol, J. Royston, and R. E. Sobol. 1995. Cytokine gene therapy with IL-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6:591.
43. Mason, D. W., M. Dallman, and A. N. Barclay. 1981. Graft-versus-host disease induces expression of la antigen in rat epidermal cells and gut epithelium. Nature 293:150.